Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
respiratory diseases
Biotech
GSK's long-acting asthma drug halved attacks in phase 3
Depemokimab was shown to reduce asthma exacerbations by 54% over 52 weeks when compared to placebo.
James Waldron
Sep 9, 2024 9:30am
GSK's SWIFT trials show long-acting treatment reduces attacks
May 21, 2024 2:00am
Surrozen's Wnt mimetic antibody works in mice with lung fibrosis
Apr 4, 2024 4:30am
Clario buys AI firm ArtiQ, taps CEO to head AI strategy
Apr 3, 2024 4:00pm
Lindus launches 'all-in-one' CRO for respiratory trials
Apr 3, 2024 12:33pm
GSK, Vir end flu drug alliance, removing key piece of $345M pact
Feb 23, 2024 5:10am